Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Regulatory Approval

Every regulatory approval filing by a US-listed company that our alert engine sent, newest first.

9:25 AM ET 8-K
Regulatory Approval Edesa Biotech, Inc. EDSA

Edesa Biotech Regulatory Approval

Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.

Counterparty
European Commission
Term
10 years
9:19 AM ET 8-K
Regulatory Approval MiniMed Group, Inc. MMED

MiniMed Group Regulatory Approval

MiniMed Group received FDA clearance for its MiniMed Fit™ patch pump, the company's first tubeless insulin pump, several months ahead of schedule. The approval triggers a $162 million one-time R&D payment obligation and has led the company to accelerate its U.S. commercial launch to Spring 2027.

8:36 AM ET 8-K
Regulatory Approval Tandem Diabetes Care Inc TNDM

Tandem Diabetes Care Regulatory Approval

Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.

4:46 PM ET 8-K
Regulatory Approval InspireMD, Inc. NSPR

InspireMD Regulatory Approval

InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.

4:08 PM ET 8-K
Regulatory Approval Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
8:32 AM ET 8-K
Regulatory Approval Mmex Resources Corp MMEX

Mmex Resources Regulatory Approval

MMEX Resources' affiliate received approval from the Texas Commission on Environmental Quality (TCEQ) for its UltraClean Refinery North facility in Pecos County. This approval, combined with a previous approval for the South facility, enables a planned refinery complex with a processing capacity of 60,000 barrels of crude oil per day.

Counterparty
Texas Commission on Environmental Quality
6:04 AM ET 8-K
Regulatory Approval Bioxytran, Inc BIXT

Bioxytran Regulatory Approval

Bioxytran secured a government-issued Free Sale Certificate for its A-SUQAR chewable nutraceutical, a key regulatory milestone for market entry in the UAE and Gulf Cooperation Council region. The certification confirms the product is lawfully manufactured and sold as a health supplement, allowing the company to proceed with product registration in markets with high diabetes prevalence.

8:42 AM ET 8-K
Regulatory Approval Viking Global Technologies, Inc. VGTK

Viking Global Technologies Regulatory Approval

Viking Global Technologies' subsidiary, Viking Ozone Technology, received formal Attestation of Conformity No. 41506-0 from the French regulator LNE for its VKIN-300 medical waste pretreatment system. The approval confirms the ozone-based disinfection technology complies with French Standard NF X 30-503-1:2024, enabling commercialization of the system in France through October 2031.

Counterparty
Laboratoire national de métrologie et d'essais (LNE)
Term
5 years
8:06 AM ET 8-K
Regulatory Approval NRX Pharmaceuticals, Inc. NRXP

NRX Pharmaceuticals Regulatory Approval

NRx Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine ahead of its November 10 goal date. The product is an American-manufactured formulation that eliminates the use of benzethonium chloride, a preservative the FDA has declined to designate as safe. The company aims to address the ongoing national shortage of ketamine using modern high-volume manufacturing technology in partnership with Nephron Pharmaceuticals.

“We are excited to bring Preservative-Free Ketamine to market and to give patients and their physicians an option for repeat treatments without the potential dangers of a preservative that has been classified as unacceptable for inclusion in multiple product categories by the US Food and Drug Administration.”

Jonathan Javitt, MD, MPH, the company’s Chairman and Chief Executive Officer
7:15 AM ET 8-K
Regulatory Approval Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Regulatory Approval

The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.

“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
8:47 AM ET 8-K
Regulatory Approval Processa Pharmaceuticals, Inc. PCSA

Processa Pharmaceuticals Regulatory Approval

Processa Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for VT-7208, allowing the company to initiate a Phase 2 study in patients with chronic spontaneous urticaria. The company also appointed Dr. Sheila Gujrathi as Executive Chair and entered into a research collaboration with Generian Pharmaceuticals to expand its pipeline.

6:03 AM ET 8-K
Regulatory Approval Supernus Pharmaceuticals, Inc. SUPN

Supernus Pharmaceuticals Regulatory Approval

The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.

Term
7 years

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals
4:17 PM ET 8-K
Regulatory Approval Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Regulatory Approval

Ionis Pharmaceuticals' partner GSK received FDA approval for HIBSAGO (bepirovirsen) for the treatment of chronic hepatitis B (CHB) in adult patients without cirrhosis. The approval, granted under priority review and Breakthrough Therapy Designation, is based on Phase 3 B-Well trials showing a 19% functional cure rate compared to less than 1% for standard of care. Ionis is eligible to receive regulatory and sales milestone payments plus tiered royalties of 10-12% on net sales.

Counterparty
GSK

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.